Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:INSM NASDAQ:ONC NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$100.42-0.2%$109.51$81.20▼$131.49$24.14B1.39925,894 shs530,361 shsINSMInsmed$143.50-1.2%$112.13$60.40▼$146.84$30.33B0.972.81 million shs2.50 million shsONCBeOne Medicines$336.26+1.3%$286.56$170.99▼$339.86$36.85B0.21428,201 shs556,401 shsVRNAVerona Pharma PLC American Depositary Share$106.17+0.1%$102.60$24.50▼$106.19$9.18B0.142.22 million shs1.06 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+0.62%-3.98%-6.26%-9.47%+14.06%INSMInsmed+6.76%+9.93%+33.68%+97.18%+90.01%ONCBeOne Medicines+8.49%+7.49%+11.05%+28.56%+33,203,999,900.00%VRNAVerona Pharma PLC American Depositary Share+0.18%+0.41%+0.87%+26.34%+286.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTXBioNTech2.0706 of 5 stars3.42.00.00.03.50.80.0INSMInsmed3.6739 of 5 stars2.53.00.04.33.10.80.6ONCBeOne Medicines0.8016 of 5 stars1.50.00.00.02.71.70.6VRNAVerona Pharma PLC American Depositary Share2.3763 of 5 stars2.15.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.76Moderate Buy$135.8035.56% UpsideINSMInsmed 2.94Moderate Buy$134.79-5.88% DownsideONCBeOne Medicines 3.00Buy$330.89-2.07% DownsideVRNAVerona Pharma PLC American Depositary Share 2.14Hold$109.002.76% UpsideCurrent Analyst Ratings BreakdownLatest VRNA, ONC, INSM, and BNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$140.00 ➝ $171.008/21/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$126.00 ➝ $144.008/20/2025INSMInsmedJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$111.00 ➝ $135.008/20/2025INSMInsmedWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform8/14/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$138.00 ➝ $136.008/14/2025INSMInsmedTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$126.00 ➝ $139.008/14/2025INSMInsmedStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$121.00 ➝ $145.008/13/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$114.00 ➝ $142.008/13/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$126.008/13/2025INSMInsmedJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$129.00 ➝ $148.008/13/2025INSMInsmedMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $165.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.98B8.09N/AN/A$87.38 per share1.15INSMInsmed$363.71M83.23N/AN/A$5.91 per share24.23ONCBeOne Medicines$3.81B9.72N/AN/A$34.40 per share9.82VRNAVerona Pharma PLC American Depositary Share$42.28M217.02N/AN/A$3.22 per share32.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$719.92M-$1.60N/AN/AN/A-12.20%-1.84%-1.59%11/3/2025 (Estimated)INSMInsmed-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)ONCBeOne Medicines-$644.79M-$1.73N/A475.90N/A-3.89%-1.22%-0.72%N/AVRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,535.83N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)Latest VRNA, ONC, INSM, and BNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025INSMInsmed-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million8/6/2025Q2 2025ONCBeOne Medicines$0.48$0.84+$0.36$0.84$1.24 billion$1.32 billion8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million8/4/2025Q2 2025BNTXBioNTech-$1.41-$1.60-$0.19-$1.82$161.26 million$306.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.618.48INSMInsmed0.456.686.33ONCBeOne Medicines0.041.951.72VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%INSMInsmedN/AONCBeOne Medicines48.55%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%INSMInsmed3.00%ONCBeOne Medicines6.62%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech6,772240.40 million194.24 millionOptionableINSMInsmed1,271211.38 million205.03 millionOptionableONCBeOne Medicines11,000109.60 million102.34 millionN/AVRNAVerona Pharma PLC American Depositary Share3086.50 million82.34 millionOptionableVRNA, ONC, INSM, and BNTX HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share $VRNA Shares Sold by Maverick Capital Ltd.September 3 at 7:29 AM | marketbeat.comArmistice Capital LLC Invests $4.33 Million in Verona Pharma PLC American Depositary Share $VRNASeptember 3 at 6:30 AM | marketbeat.comTrexquant Investment LP Purchases 32,346 Shares of Verona Pharma PLC American Depositary Share $VRNASeptember 3 at 4:51 AM | marketbeat.comVelan Capital Investment Management LP Boosts Stock Position in Verona Pharma PLC American Depositary Share $VRNAAugust 31 at 7:15 AM | marketbeat.comFORA Capital LLC Makes New Investment in Verona Pharma PLC American Depositary Share $VRNAAugust 31 at 5:04 AM | marketbeat.comHere’s How Wall Street is Reacting to Verona Pharma (VRNA)’s AcquisitionAugust 28, 2025 | finance.yahoo.comAffinity Asset Advisors LLC Reduces Holdings in Verona Pharma PLC American Depositary Share $VRNAAugust 28, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Has $118.49 Million Stock Holdings in Verona Pharma PLC American Depositary Share $VRNAAugust 27, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives $109.00 Average Target Price from AnalystsAugust 27, 2025 | americanbankingnews.comAmerican Century Companies Inc. Sells 310,985 Shares of Verona Pharma PLC American Depositary Share $VRNAAugust 26, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given Consensus Recommendation of "Hold" by BrokeragesAugust 26, 2025 | marketbeat.com10,635 Shares in Verona Pharma PLC American Depositary Share $VRNA Purchased by Jasper Ridge Partners L.P.August 25, 2025 | marketbeat.com87,402 Shares in Verona Pharma PLC American Depositary Share $VRNA Acquired by Russell Investments Group Ltd.August 24, 2025 | marketbeat.comAtika Capital Management LLC Cuts Stock Position in Verona Pharma PLC American Depositary Share $VRNAAugust 23, 2025 | marketbeat.comCandriam S.C.A. Reduces Holdings in Verona Pharma PLC American Depositary Share $VRNAAugust 23, 2025 | marketbeat.comWellington Management Group LLP Has $135.33 Million Stock Holdings in Verona Pharma PLC American Depositary Share $VRNAAugust 23, 2025 | marketbeat.comShort Interest in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Declines By 39.2%August 21, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Reaches New 12-Month High - Should You Buy?August 20, 2025 | marketbeat.comTokio Marine Asset Management Co. Ltd. Makes New $698,000 Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 18, 2025 | marketbeat.comLPL Financial LLC Purchases 20,500 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 18, 2025 | marketbeat.comLord Abbett & CO. LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Tesla’s Pennant Just Snapped: Here’s What It Means for the StockBy Sam Quirke | August 14, 20253 Tariff-Proof Retailers Making New All-time HighsBy Dan Schmidt | September 1, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025VRNA, ONC, INSM, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$100.42 -0.20 (-0.20%) Closing price 04:00 PM EasternExtended Trading$100.49 +0.07 (+0.07%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Insmed NASDAQ:INSM$143.50 -1.80 (-1.24%) Closing price 04:00 PM EasternExtended Trading$143.16 -0.34 (-0.24%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.BeOne Medicines NASDAQ:ONC$336.26 +4.22 (+1.27%) As of 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$106.17 +0.07 (+0.07%) Closing price 04:00 PM EasternExtended Trading$106.16 -0.01 (-0.01%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
